<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02583126</url>
  </required_header>
  <id_info>
    <org_study_id>GIM-Cancer-Teenagers-1</org_study_id>
    <nct_id>NCT02583126</nct_id>
  </id_info>
  <brief_title>Guided Imagery and Music for the Reduction of Side Effects of Chemotherapy in Teenagers</brief_title>
  <official_title>The Effect and Meaning of a Designed Guided Imagery and Music Intervention on Anticipatory, Acute, and Delayed Side Effect of Chemotherapy in Teenagers With Cancer: a Randomized Controlled Multisite Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Danish Cancer Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Børnecancerfonden</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ronald McDonalds Børnefond</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>TrygFonden, Denmark</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether a modified and resource-oriented form of
      Guided Imagery and Music (GIM) is effective in reducing side effects of chemotherapy in
      teenagers with cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      (Will be added later)
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2014</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Duration (minutes) of Acute Nausea</measure>
    <time_frame>Registered the two first evenings within the first 32 hours after onset of chemotherapy during 5th cycle of chemotherapy after enrolment in study</time_frame>
    <description>Self-reported duration og nausea in minutes during the first 32 hours after onset of chemotherapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intensity of Acute Nausea as measured by the Visual Analogue Scale</measure>
    <time_frame>Registered the two first evenings within the first 32 hours after onset of chemotherapy during 5th cycle of chemotherapy after enrolment in study</time_frame>
    <description>Self-reported intensity of nausea, calculated as the average of the two measurements</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distress regarding Acute Nausea as measured by the Visual Analogue Scale</measure>
    <time_frame>Registered the two first evenings within the first 32 hours after onset of chemotherapy during 5th cycle of chemotherapy after enrolment in study</time_frame>
    <description>Self-reported distress regarding nausea, calculated as the average of the two measurements</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount (mg/m2) of Nausea Reducing Medicine Consumed</measure>
    <time_frame>During admission (an expected average of 3 days) and the first three days after discharge regarding 5th cycle of chemotherapy after enrolment in study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple Acute Side Effects of Chemotherapy as measured by the Memorial Symptom Assessment Scale</measure>
    <time_frame>Registered the two first evenings within the first 32 hours after onset of chemotherapy during 5th cycle of chemotherapy after enrolment in study</time_frame>
    <description>Self-reported side effects, calculated as the average of the two measurements. The Memorial Symptom Assessment Scale is a self-report composite measure that measures bodily and psychological symptoms of side effects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Numbers of Acute Vomiting</measure>
    <time_frame>Registered the two first evenings within the first 32 hours after onset of chemotherapy during 5th cycle of chemotherapy after enrolment in study</time_frame>
    <description>Self-reported numbers of vomiting during the first 32 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration (minutes) of Acute Pain</measure>
    <time_frame>Registered the two first evenings within the first 32 hours after onset of chemotherapy during 5th cycle of chemotherapy after enrolment in study</time_frame>
    <description>Self-reported duration of acute pain in minutes within the first 32 hours after onset of chemotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute Pain Intensity as measured by the Visual Analogue Scale</measure>
    <time_frame>Registered the two first evenings within the first 32 hours after onset of chemotherapy during 5th cycle of chemotherapy after enrolment in study</time_frame>
    <description>Self-reported intensity of pain, calculated as the average of the two measurements</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Days to Absolute Neutrophil Count Recovery defined as ANC ≥ 0.5 x 109/L</measure>
    <time_frame>Time to Event: Measured Day 1 in 5th cycle of chemotherapy after enrolment in study - until first day with ANC ≥ 0.5 x 109/L after the nadir period (an expected average of 9-15 days)</time_frame>
    <description>Number of days before the immune system recovers after chemotherapy. In the study, Absolute Neutrophil Count Recovery (ANCR) is defined as ANCR ≥ 0.5 x 109/L. In addition, if no nadir &lt; 0.5 x 109/L occurs the period is 0 (zero).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration (minutes) of Acute Fatigue</measure>
    <time_frame>Registered the two first evenings within the first 32 hours after onset of chemotherapy during 5th cycle of chemotherapy after enrolment in study</time_frame>
    <description>Self-reported duration of acute fatigue in minutes within the first 32 hours after onset of chemotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distress regarding Acute Fatigue as measured by a 5-point Likert-type Scale</measure>
    <time_frame>Registered the two first evenings within the first 32 hours after onset of chemotherapy during 5th cycle of chemotherapy after enrolment in study</time_frame>
    <description>Self-reported Distress regarding Acute Fatigue, calculated as the average of the two measurements</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Appraised food intake and appetite as measured by a 5-point Likert-type Scale</measure>
    <time_frame>Registered the two first evenings within the first 32 hours after onset of chemotherapy during 5th cycle of chemotherapy after enrolment in study</time_frame>
    <description>Self-reported appraised food intake, calculated as the average of the two measurements</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight (kg)</measure>
    <time_frame>Change between weight from during course 1 and course 5 after inclusion in study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sense of Coherence as measured by the Antonovsky Sense of Coherence Scale</measure>
    <time_frame>Last day (i.e. expected 3rd or 4th day) of 5th cycle of chemotherapy after enrolment in study</time_frame>
    <description>Self-report, registered once during 5th cycle of chemotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satisfaction with music intervention as measured by a Likert-type Scale (participants in music group only)</measure>
    <time_frame>Last day (i.e. expected 3rd or 4th day) of 5th cycle of chemotherapy after enrolment in study</time_frame>
    <description>Self-report, registered once during 5th cycle of chemotherapy</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">68</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Music Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prescribed medical/chemotherapy treatment plus standard care + Guided Imagery and Music</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Prescribed medical/chemotherapy treatment plus standard care</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Guided Imagery and Music</intervention_name>
    <description>Modified and resource-oriented form of the Bonny Method of Guided Imagery and Music (BM-GIM)</description>
    <arm_group_label>Music Group</arm_group_label>
    <other_name>Music and imagery, music therapy, active music listening</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Teenagers at the ages 12-17

          2. Four or five (dependent on their overall plan of medical treatment) consecutive
             courses of chemotherapy administrated at the involved child cancer units and
             (administered) over a period of minimum 24 hours incl. hydration with assumed moderate
             to severe nausea and vomiting.

             The specific type of chemotherapy may vary across the four/five consecutive courses
             but shall include one of the following moderate and/or highly emetogenic types of
             chemotherapy:

             Moderate emetogenic chemotherapy:

               -  Carboplatin

               -  Cyclophosphamide &lt;1500 mg/m2

               -  Cytarabine &gt;1 g/m2

               -  Daunorubicin

               -  Doxorubicin

               -  Epirubicin

               -  Idarubicin

               -  Ifosfamide

               -  Mitoxantrone

               -  Methotrexate &gt;1000 mg/m2

             Highly emetogenic chemotherapy:

               -  Cisplatin &gt;25 mg/m2

               -  Cyclophosphamide &gt;1500 mg/m2

               -  Dacarbazine

          3. Understand Norwegian/Danish

          4. Read Norwegian/Danish (teenagers or alternatively parents)

          5. No significant hearing impairment

          6. Informed written consent (teenagers ≥16 years and parents)

          7. Subsequent verbal confirmation of written informed consent before enrolment in study

        Exclusion Criteria:

          1. Previous and/or acute psychiatric diagnosis

          2. Cognitive and mental deficits or impaired functioning
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ilan Sanfi, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aarhus University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ilan Sanfi, PhD</last_name>
    <phone>+45 22973661</phone>
    <email>ilan@sanfi.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stine Camilla Ærø, BA</last_name>
    <phone>+47 92498316</phone>
    <email>sero@ous-hf.no</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisbeth Rasmussen</last_name>
      <phone>+45 78 45 14 70</phone>
      <email>lisbeth.rasmussen@skejby.rm.dk</email>
    </contact>
    <investigator>
      <last_name>Ilan Sanfi, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Henrik Hasle, Prof. PhD MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 3, 2015</study_first_submitted>
  <study_first_submitted_qc>October 19, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 22, 2015</study_first_posted>
  <last_update_submitted>November 30, 2015</last_update_submitted>
  <last_update_submitted_qc>November 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 2, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Aarhus University Hospital</investigator_affiliation>
    <investigator_full_name>Ilan Sanfi</investigator_full_name>
    <investigator_title>Music therapist, PhD</investigator_title>
  </responsible_party>
  <keyword>Teenager</keyword>
  <keyword>moderate and/or highly emetogenic chemotherapy</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

